Avalon Trust’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31.6K Hold
521
﹤0.01% 331
2025
Q4
$28.1K Sell
521
-1,344
-72% -$64.7K ﹤0.01% 333
2025
Q3
$84.1K Buy
1,865
+19
+1% +$887 0.01% 251
2025
Q2
$85.5K Sell
1,846
-651
-26% -$32K 0.01% 211
2025
Q1
$152K Buy
2,497
+1,976
+379% +$115K 0.01% 151
2024
Q4
$29.5K Hold
521
﹤0.01% 272
2024
Q3
$27K Hold
521
﹤0.01% 250
2024
Q2
$21.6K Hold
521
﹤0.01% 259
2024
Q1
$28.3K Hold
521
﹤0.01% 250
2023
Q4
$26.7K Hold
521
﹤0.01% 248
2023
Q3
$30.2K Hold
521
﹤0.01% 210
2023
Q2
$33.3K Hold
521
﹤0.01% 224
2023
Q1
$36.1K Buy
+521
New +$36.7K ﹤0.01% 216

Other funds holding BMY

Avalon Trust's BMY Position: Q1 2026 in Review

Avalon Trust held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 521 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #331.

Avalon Trust first reported a position in BMY in Q1 2023 and has held it in 13 quarters since. The position peaked at $152K in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Avalon Trust held 521 shares of Bristol-Myers Squibb worth $31.6K as of Q1 2026.
  • Avalon Trust left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up ﹤0.01% of Avalon Trust's portfolio in Q1 2026, its #331 holding.
  • Avalon Trust first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 13 quarters since.
  • Avalon Trust's Bristol-Myers Squibb position peaked at $152K in Q1 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Avalon Trust's 13F filing for Q1 2026, filed 6 May 2026.